Company: APM
Filing Date: 2025-10-06
Form Type: S-4
Source: 0001213900-25-096656
Chunk: 367

Company: Aptorum Group Ltd
Filing Date: 2025-10-06
Form: S-4
Chunk 367
---
 than 5 years old, 5 to 15 years old, and older than 16 years old. The blood samples for the study were provided by the Tri -StateRett Syndrome Center, Montefiore Medical Center. In line with DiamiR’s previously described results (see Business section, Circulating Organ -enrichedmiRNAs as Biomarkers of Rett Syndrome), the microRNA panel effectively differentiated study participants with Rett syndrome. 209 To develop a marketable RTT diagnostic solution, DiamiR plans to offer both sequencing services (of the MECP2gene) and its proprietary miRNA panel. DiamiR is currently evaluating 3 rdparty vendors to develop a custom NGS assay for Rett syndrome on a MiSeQ platform (Illumina). BEYOND BRAIN HEALTH: UNIVERSAL SCREENING TEST DiamiR believes its core miRNA technology is robust and applicable to early detection of disease pathology in different organs, not only in the brain, which enables a novel approach to screening whereby a battery of screening tests relying on organ -enrichedmiRNAs detect the presence of pathology in a given organ; where the detection of a pathology in an organ can result in more specific (and possibly expensive and or invasive) testing for a differential diagnosis of the disease. In a proof -of-conceptstudy, miRNA pairs comprised of select miRNAs enriched in the organs of the gastrointestinal (GI) and pulmonary systems effectively differentiated respective pathologies of the GI (esophageal, gastric or colon cancers (stages I and II), and Crohn’s disease) and lung (pneumonia, asthma, and non -smallcell lung cancer (40% with stages I and II)) systems from age -matchedcontrols and from each other with an overall accuracy of 90 -96%. The figure below summarizes the approach and principal findings: (Journal of Translational Medicine, 2013, 11:304) ANALYTICAL PLATFORM FOR PLASMA miRNA DETECTION In 2023, DiamiR completed an analytical validation of plasma miRNA detection in DiamiR CLIA laboratory. The platform is based on Qiagen’s LNA qPCR technology. In this study, published in a peer -reviewedpublication and reported at several scientific meetings (below), DiamiR has demonstrated that the 24 miRNA biomarker candidates comprising CogniMIR ®panel, as well as additional miRNAs showing promise as RTT biomarker candidates,